506 related articles for article (PubMed ID: 18515791)
61. Comparison of the hypotensive and diuretic effects of 1,4-dimorpholino-7-phenylpyrido[3,4]pyridazine (DS-511) and hydrochlorothiazide in Doca, renal and spontaneously hypertensive rats.
Inada Y; Nishikawa K; Nagaoka A; Kikuchi S
Arzneimittelforschung; 1977; 27(9):1663-9. PubMed ID: 579134
[TBL] [Abstract][Full Text] [Related]
62. Decreased penile erection in DOCA-salt and stroke prone-spontaneously hypertensive rats.
Chitaley K; Webb RC; Dorrance AM; Mills TM
Int J Impot Res; 2001 Dec; 13 Suppl 5():S16-20. PubMed ID: 11781742
[TBL] [Abstract][Full Text] [Related]
63. Expression of mineralocorticoid receptors mRNA in the brain, heart and kidney of Sprague Dawley rats with renovascular hypertension.
Jackiewicz E; Szczepańska-Sadowska E; Maśliński W
Brain Res Bull; 2005 Feb; 65(1):23-9. PubMed ID: 15680542
[TBL] [Abstract][Full Text] [Related]
64. Mineralocorticoid receptor--Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats.
Kawarazaki H; Ando K; Shibata S; Muraoka K; Fujita M; Kawarasaki C; Fujita T
J Hypertens; 2012 Oct; 30(10):1977-85. PubMed ID: 22914542
[TBL] [Abstract][Full Text] [Related]
65. Changes in the composition of the thoracic aortic wall in spontaneously hypertensive rats treated with losartan or spironolactone.
Han WQ; Wu LY; Zhou HY; Zhang J; Che ZQ; Wu YJ; Liu JJ; Zhu DL; Gao PJ
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):583-8. PubMed ID: 19673944
[TBL] [Abstract][Full Text] [Related]
66. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis.
Iwazu Y; Muto S; Fujisawa G; Nakazawa E; Okada K; Ishibashi S; Kusano E
Hypertension; 2008 Mar; 51(3):749-54. PubMed ID: 18250361
[TBL] [Abstract][Full Text] [Related]
67. CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats.
Arai K; Morikawa Y; Ubukata N; Tsuruoka H; Homma T
J Pharmacol Exp Ther; 2016 Sep; 358(3):548-57. PubMed ID: 27384074
[TBL] [Abstract][Full Text] [Related]
68. [Brain mineralocorticoid receptor and blood pressure control in the conscious normotensive rat].
Rahmouni K; Barthelmebs M; Imbs JL; De Jong W
Arch Mal Coeur Vaiss; 1998 Aug; 91(8):1009-12. PubMed ID: 9749155
[TBL] [Abstract][Full Text] [Related]
69. Ouabain as an amplifier of mineralocorticoid-induced hypertension.
Sekihara H; Yazaki Y; Kojima T
Endocrinology; 1992 Dec; 131(6):3077-82. PubMed ID: 1446641
[TBL] [Abstract][Full Text] [Related]
70. [The parathyroids and desoxycorticosterone acetate induced arterial hypertension in the rat].
Berthelot A; Schleiffer R; Gairard A
Can J Physiol Pharmacol; 1979 Feb; 57(2):157-62. PubMed ID: 546483
[TBL] [Abstract][Full Text] [Related]
71. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats.
Elmarakby AA; Quigley JE; Imig JD; Pollock JS; Pollock DM
Am J Physiol Regul Integr Comp Physiol; 2008 Jan; 294(1):R76-83. PubMed ID: 17989143
[TBL] [Abstract][Full Text] [Related]
72. Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension.
Banes AK; Watts SW
Hypertension; 2002 Feb; 39(2 Pt 2):394-8. PubMed ID: 11882579
[TBL] [Abstract][Full Text] [Related]
73. Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.
Ling YH; Krishnan SM; Chan CT; Diep H; Ferens D; Chin-Dusting J; Kemp-Harper BK; Samuel CS; Hewitson TD; Latz E; Mansell A; Sobey CG; Drummond GR
Pharmacol Res; 2017 Feb; 116():77-86. PubMed ID: 27986554
[TBL] [Abstract][Full Text] [Related]
74. Sodium butyrate ameliorates deoxycorticosterone acetate/salt-induced hypertension and renal damage by inhibiting the MR/SGK1 pathway.
Wu C; Chen Z; Zhang L; Zhu Y; Deng M; Huang C; Liu Y; Zhu Q; Wang L
Hypertens Res; 2021 Feb; 44(2):168-178. PubMed ID: 32908237
[TBL] [Abstract][Full Text] [Related]
75. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.
Vallon V; Wyatt AW; Klingel K; Huang DY; Hussain A; Berchtold S; Friedrich B; Grahammer F; Belaiba RS; Görlach A; Wulff P; Daut J; Dalton ND; Ross J; Flögel U; Schrader J; Osswald H; Kandolf R; Kuhl D; Lang F
J Mol Med (Berl); 2006 May; 84(5):396-404. PubMed ID: 16604333
[TBL] [Abstract][Full Text] [Related]
76. Structural change in the rat hindlimb during deoxycorticosterone acetate hypertension; its reversibility and prevention.
Vial JH; Yong AC; Boyd GW
J Hypertens; 1989 Feb; 7(2):143-50. PubMed ID: 2522477
[TBL] [Abstract][Full Text] [Related]
77. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
de Resende MM; Kriegel AJ; Greene AS
J Cardiovasc Pharmacol; 2006 Dec; 48(6):265-73. PubMed ID: 17204904
[TBL] [Abstract][Full Text] [Related]
78. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
79. [A simplified method for preparation of DOCA-salt hypertension model in rats by subcutaneous implantation of DOCA silastic tube].
Wang Q; Chen Z; Fan XP; Xu DH; Zhou GH; Liang ZX
Sheng Li Xue Bao; 1994 Apr; 46(2):205-8. PubMed ID: 7973805
[TBL] [Abstract][Full Text] [Related]
80. The effect of estrogen on serum nitric oxide concentrations in normotensive and DOCA Salt hypertensive ovariectomized rats.
Nematbakhsh M; Khazaei M
Clin Chim Acta; 2004 Jun; 344(1-2):53-7. PubMed ID: 15149870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
